SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly
LLY 1,074+0.3%9:55 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kas1 who wrote (348)10/2/1998 11:38:00 AM
From: Anthony Wong  Read Replies (2) of 642
 
(OT) Kas1, concerning AHP, their pipeline drugs don't seem to be that exciting or "blockbuster" (Enbrel for rheumatoid arthritis, Rapamune for prevention of transplant rejection etc.) Hence merger with MTC would be a great positive for them. I prefer MTC on the very slim chance that another pharma would come in to make a competing bid for MTC. I believe there are some lawsuits against AHP's obesity drugs. This could be a drag on the stock price.

BTW, AHP would report earnings on 10/22.

Regards.

Anthony
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News